9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

CAR T Cells in Mesothelin Expressing Cancers

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > CAR T Cells in Mesothelin Expressing Cancers

CAR T Cells in Mesothelin Expressing Cancers

Estimated reading time: < 1 min

Condition: Lung Adenocarcinoma

Estimated Enrollment: 30

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,  Clinical anti-tumor effect by standard criteria (RECIST),  Clinical anti-tumor effect by standard criteria [modified RECIST for mesothelioma], Progression-free survival

Interventions: huCART-meso cells,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: March 2021

Completion Date: March 2021

Last  Posted Date: April 18, 2019

Location: University of Pennsylvania, Philadelphia, Pennsylvania, United States

Website Link: https://ClinicalTrials.gov/show/NCT03054298

Was this article helpful?
Dislike 0